In the cerivastatin group, (n=1,303), the percentage of patients achieving NCEP-ATP II/ADA goals was 55.5% in the pre-conversion period and 73.7% in the post-conversion period.
The corresponding percentages changed from 45.5% to 63.75% in the secondary prevention subgroup, from 29.66% to 49.66% in the diabetes subgroup, from 65.84% to 84.77% in the 2 or more RF subgroup, and from 77.82% to 94.14% in the fewer than 2 RF subgroup.
In the simvastatin group, (n=265), the percentage of patients achieving NCEP-ATP II/ADA goals was 45.7% in the pre-conversion period and 69.8% in the post-conversion period.
The corresponding percentages changed from 35.2% to 59.1% in the secondary prevention subgroup, from 21.2% to 69.7% in the diabetes subgroup, from 54.7% to 77.4% in the 2 or more RF subgroup, and from 75% to 88.5% in the fewer than 2 RF subgroup.
In the cerivastatin group, LDL-C values changed from 118.9 to 103.5 mg/dl, TC values changed from 201.2 to 187.7 mg/dl, HDL-C varied from 46.2 to 50 mg/dl, and TG values changed from 180.6 to 170.4 mg/dl.
In the simvastatin group, LDL-C values changed from 121.4 to 102.3 mg/dl, TC values changed from 204.8 to 185.9 mg/dl, HDL-C varied from 45.8 to 47.6 mg/dl, and TG values changed from 188.1 to 180.1 mg/dl.
Similar trends were observed in the subgroup analysis.
All the changes between the pre- and post-conversion periods reached statistical significance with the exception of the change of TG values in the simvastatin group.
There were only three adverse events in the cerivastatin group and two events in the simvastatin group.